p53 is a crucial tumor suppressor that is mutated or deleted in a majority of cancers. Exactly how p53 prevents tumor progression has proved elusive for many years; however, this information is crucial to define targets for chemotherapeutic development that can effectively restore p53 function. Bioactive sphingolipids have recently emerged as important regulators of proliferative, apoptotic and senescent cellular processes. In this study, we demonstrate that the enzyme sphingosine kinase 1 (SK1), a critical enzyme in the regulation of the key bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phosphate (S1P), serves as a key downstream target for p53 action. Our results show that SK1 is proteolysed in response to genotoxic stress in a p53-dependent manner. p53 null mice display elevation of SK1 levels and a tumorpromoting dysregulation of bioactive sphingolipids in which the anti-growth sphingolipid ceramide is decreased and the pro-growth sphingolipid S1P is increased. Importantly, deletion of SK1 in p53 null mice completely abrogated thymic lymphomas in these mice and prolonged their life span by B30%. Deletion of SK1 also significantly attenuated the formation of other cancers in p53 heterozygote mice. The mechanism of p53 tumor suppression by loss of SK1 is mediated by elevations of sphingosine and ceramide, which in turn were accompanied by increased expression of cell cycle inhibitors and tumor cell senescence. Thus, targeting SK1 may restore sphingolipid homeostasis in p53-dependent tumors and provide insights into novel therapeutic approaches to cancer.
Introduction
Cancer is a complex process in which aberrant growth signals lead to the expansion of damaged cells that would normally not proliferate. Discerning the intricate molecular mechanisms that lead to tumor growth should enable the development of more effective cancer therapies that target them (Lees and Weinberg, 1999; Kang et al., 2005) . One class of molecules that have emerged as critical regulators of several cellular processes of direct relevance to cancer, including growth, differentiation, apoptosis and senescence are the bioactive sphingolipids (Hannun and Obeid, 2008; Pruett et al., 2008; Pyne and Pyne, 2010) . Dysregulation of sphingolipid metabolic pathways has been demonstrated in several cancers, suggesting that alterations in sphingolipid metabolism may represent an important step in tumorigenesis (Cuvillier and Levade, 2003; Long et al., 2010; Watson et al., 2010; Ryland et al., 2011) .
SK1 holds a crucial position in sphingolipid metabolism with its function required for homeostatic processing of the pro-apoptotic sphingolipids, ceramide and sphingosine. Moreover, the product of sphingosine kinase 1 (SK1), sphingosine-1-phosphate (S1P), is not only a metabolic intermediate required for exit from the sphingolipid metabolic pathway, but has been shown to act as a pro-growth signal in stark contrast to the functions of its upstream sphingolipid family members (Pitson, 2011) . Thus, it appears that SK1 acts as a balance between pro-death and pro-growth bioactive signaling lipids and, intuitively, alterations in this enzyme's activity could be involved in carcinogenesis. Indeed, previous work from our lab showed that SK1 message levels are universally increased in various types of human cancers (Johnson et al., 2005) . Furthermore, multiple independent studies have shown that the SK1/ S1P pathway has a role in cancer cell growth and viability and in the resistance of tumors to chemotherapy (Akao et al., 2006; Bayerl et al., 2008; Pchejetski et al., 2008; Li et al., 2009; Long et al., 2010; Watson et al., 2010) .
Similar oncogenic properties have long been attributed to the loss of the tumor-suppressor p53 (also known as TP53), which has been the most studied tumor-suppressor protein because of its involvement in 450% of human cancers (Vogelstein and Levine, 2000; Soussi, 2007; Weisz et al., 2007) . Since alteration of p53 signaling has been recognized as a central component of human carcinogenesis, nearly 20 different types of genetically modified mice targeting p53 in various ways have been made over the past 20 years to aid in the study of this medically relevant tumor suppressor (Soussi, 2007; Zilfou and Lowe, 2009 ). The most common phenotype observed in mice that lack both p53 alleles is decreased survival because of their development of thymic lymphoma, whereas in mice that lack only one p53 allele, osteosarcomas and soft tissue sarcomas predominate, and animal survival is not as dramatically decreased as in complete knockout (KO) animals (Donehower et al., 1992; Jacks et al., 1994; Lozano) . Thus, p53-deficient mice can serve as an appropriate in vivo model for the study of carcinogenesis in multiple tissues.
Interestingly, some studies have suggested a link between the p53 tumor-suppressor protein and bioactive sphingolipids, especially ceramide and S1P (Pruschy et al., 1999; Lopez-Marure et al., 2000; Oskouian et al., 2006) as reviewed in (Heffernan-Stroud and Obeid, 2011) . Genotoxic stress has been shown to induce the pro-apoptotic sphingolipid, ceramide in a p53-dependent manner (Dbaibo et al., 1998) , and, indeed, several inducers of apoptosis have been shown to increase ceramide in cells concomitant with p53 activation (Kim et al., 2002; ElAssaad et al., 2003; Sawada et al., 2004) . Moreover, we found that treatment of Molt-4 T-cell leukemia cells with the DNA-damaging agent actinomycin D results in degradation of SK1, the key enzyme that regulates the balance between ceramides, sphingosine and S1P. Importantly, these effects were not observed in cells overexpressing the papilloma virus E6 protein, which targets p53 to degradation, suggesting a role for p53 in this process (Taha et al., 2004) . Furthermore, Oskouian et al. (2006) showed that overexpression of the enzyme that breaks down S1P, S1P lyase, can potentiate an apoptotic response to DNA damage in a p53-dependent manner. These studies suggest that some of the enzymes controlling ceramide and S1P levels in cells may act as effectors/modulators of the p53 tumor-suppressor pathway; however, the mechanisms and significance of these relations to sphingolipids are not known.
As SK1 message levels are universally increased in various types of cancers (Johnson et al., 2005) and p53 may regulate SK1 in response to genotoxic stress in leukemia cells, we hypothesized that dysregulation of the SK1/S1P pathway could be involved in p53-altered cancers. To test this hypothesis, we evaluated the p53-dependent regulation of SK1 in mouse non-cancer cells as well as SK1 expression in p53 null tumors. Next, we evaluated the effect of genetic ablation of SK1 in p53 KO mice on spontaneous tumor development and survival to determine if restoration of the sphingolipid profile could offer protective tumor cell senescence. Finally, we expanded these studies to include other tissue/tumor types by crossing SK1 KO mice with p53 heterozygote mice and assessing the effects of SK1 gene dosage on tumorigenesis and survival.
Results

p53 negatively regulates SK1
First, we set out to investigate a mechanistic connection among genotoxic stress, p53 and SK1. To this end, we utilized mouse embryonic fibroblasts (MEFs) from wildtype (WT) and p53 KO mice and evaluated the effects of ultraviolet irradiation on SK1. We found that induction of p53 was required for a reduction in SK1 protein to occur following genotoxic stress (Figure 1a) , thus, establishing p53 as an upstream regulator of sphingolipid metabolism. These studies also revealed that p53-dependent downregulation of SK1 was occurring at the protein, rather than message level (Figures 1a  and b ). Additionally, we were able to inhibit the effects of p53-mediated genotoxic stress on SK1 with a caspase-2 inhibitor, suggesting proteolytic degradation as the mechanism of p53-dependent SK1 regulation ( Figure 1c ) as is consistent with previous studies suggesting regulation of SK1 through proteolysis (Taha et al., 2005; Loveridge et al., 2010) . This finding is also in keeping with several reports showing p53-dependent activation of caspase-2 (Baptiste- Okoh et al., 2008; Cuenin et al., 2008; Vakifahmetoglu et al., 2008; Ho et al., 2009) . We found that genotoxic stress led to p53-dependent downregulation of SK1, which, in turn, decreased the pro-growth signaling product of SK1, S1P (Figure 1d ). Importantly, this downregulation of SK1 also led to the accumulation of the upstream, antigrowth signaling sphingolipid, ceramide (Figure 1d ). This regulation of SK1 and these potentially tumorsuppressive changes in sphingolipid signaling molecules required p53 (Figure 1d ), and could constitute an important component of the p53 tumor-suppressor pathway.
In light of these results, we hypothesized that cells lacking p53 would lack proper regulation of SK1. Indeed, treating WT, p53 KO, SK1 KO and double knockout (DKO) MEFs with a shorter chain-containing substrate for SK1, C17-sphingosine, showed increased production of C17-S1P in the p53 KO cells (Figure 2a ). These studies also confirmed that the main enzyme responsible for S1P production in these cells is SK1 rather than SK2, because very little S1P was produced in cells lacking SK1 ( Figure 2a) . Next, we investigated whether p53 was required for the regulation of SK1 in vivo. As p53 KO mice develop thymic lymphomas (Donehower et al., 1992; Jacks et al., 1994) , we compared SK1 expression and activity in the thymus glands of WT and p53 KO mice at 60 days of age, a time during which there is negative selection and significant cell turnover in the developing murine thymus. Consistent with our cellular studies, we observed no differences in SK1 message levels between WT and p53 KO thymus glands (Supplementary Figure  1) . In contrast, using immunohistochemistry, we observed more intense staining for SK1 protein in tissues lacking regulatory p53 when compared with those with WT p53 (Figure 2b ). In addition, SK1 activity was significantly increased in tissues lacking p53 (Figure 2c ), demonstrating that SK1 is deregulated which can lead to changes in sphingolipid metabolism that signal for tumor-promotion in the thymic tissue of p53 KO mice. Spontaneous tumor formation in p53 KO mice requires SK1 Next, we investigated the functional consequences of p53 effects on SK1. Ceramide exerts apoptotic and growth-suppressive effects (Obeid et al., 1993; Jayadev et al., 1995; Kolesnick and Fuks, 2003) , whereas S1P exerts opposing anti-apoptotic and pro-growth effects (Olivera and Spiegel, 1993; Lee et al., 1998; Olivera et al., 1999) ; indeed, ceramide has been proposed as a tumor-suppressor lipid and S1P as a tumor-promoting lipid (Cuvillier et al., 1996; Hannun and Obeid, 2008) . Therefore, to determine if SK1 deregulation in p53 KO mice contributes to tumor development, we crossed p53 KO mice (Jacks et al., 1994) with SK1 KO mice (Allende et al., 2004) to ascertain whether enforced SK1 downregulation was protective against carcinogenesis. We initially focused on thymic lymphoma as the major and most consistent tumor in p53 KO mice (Donehower et al., 1992; Jacks et al., 1994) . The results revealed a significant and gene-dosage-dependent effect in which tumor burden was decreased in p53 KO mice lacking a single SK1 allele. Remarkably, p53 KO mice lacking both SK1 alleles were almost totally protected from thymic lymphoma development, compared with p53 KO mice expressing WT SK1 (Figure 3a) . In necropsy studies, thymic mass decreased with loss of SK1 expression in p53 KO mice (Figure 3b) , and histological evaluation confirmed protection from thymic lymphoma in the DKO mice (Figure 3c ). Such protection from carcinogenesis in the DKO mice led to increases in median survival by 436%, compared with p53 KO mice expressing both SK1 alleles (Figure 3d ). These results suggest that deregulation of SK1 in p53 KO mice may contribute to early tumor development and that SK1 KO could protect these mice from thymic lymphoma development thereby increasing survival.
Decreased tumor burden in p53-SK1 double KO mice via induction of cellular senescence To investigate how KO of SK1 protects p53 KO mice from the development of thymic lymphoma, we first measured sphingolipids in thymus glands from mice with varied p53 and SK1 expression including p53 WT SK1 WT (WT), p53KO SK1 WT (p53 KO), p53 WT SK1 KO (SK1 KO) and p53 KO SK1 KO (DKO). Consistent with deregulated SK1 activity (Figure 2c ), thymic tissue from p53 KO mice had decreased upstream sphingolipid ceramide and increased S1P, the product of SK1 (Figure 4a ). The p53 KO thymus glands also had increased sphingosine (Figure 4a ), which could indicate decreased activity of a ceramide synthase, but most likely indicates increased ceramide breakdown by a ceramidase (Supplementary Figure 1) . As expected, thymus glands from SK1 KO mice contained significantly less S1P and more sphingosine than those from WT mice (Figure 4a ). Of note, KO of SK1 suppressed the pro-growth signaling sphingolipid, S1P, in the p53 KO mice to that of WT levels (Figure 4a) . Similarly, KO of SK1 also restored the levels of the anti-growth ceramide to WT levels in the thymic tissue of DKO mice (Figure 4a ), demonstrating a role for SK1 in maintaining ceramide homeostasis. Taken together, these results show significant effects of p53 (and its loss) on the levels of bioactive sphingolipids. The results also implicate SK1 in mediating these changes.
Similar changes were also observed for sphingolipids in the blood of these mice (Supplementary Figure 2) . Thus, KO of SK1 seemed to function to re-balance these two bioactive sphingolipids to WT levels in p53 KO tissues. However, sphingosine was significantly increased in DKO tissue compared with either KO mouse alone (Figure 4a , middle panel). Again these changes are consistent with decreased phosphorylation of sphingosine with KO of SK1, but also suggest an increase in ceramide catabolism with KO of p53. Overall, our data suggest that KO of SK1 protects p53 KO mice from tumor development by restoring dysregulated ceramide and S1P in these tissues to those of WT levels.
To determine the pathophysiologic significance of bioactive sphingolipid dysregulation, we analyzed thymic tissue from mice of the four genotypes for apoptosis and senescence, functions known to be reciprocally regulated by ceramide and S1P (Taha et al., 2006; Hannun and Obeid, 2008) . First, we suspected that a decrease in ceramide and the increase in S1P in p53 KO thymus glands may predispose these mice to carcinogenesis as a result of an inadequate apoptotic response. However, we did not find a significant difference between genotypes in the percentage of apoptotic cells present in the thymus glands (Figure 4b ). When split into T-cell subtypes, p53 KO thymi had decreased apoptosis of double-positive T cells, but this was offset by increased apoptosis of double-negative and singlepositive CD8 þ cells (Supplementary Figure 3) . However, such differences in apoptosis among the cell subtypes appeared as minor differences in overall cell population between genotypes rather than differential susceptibility to apoptosis (Supplementary Figure 3) . Therefore, we concluded that a decrease in apoptosis was not responsible for the increased thymus size observed in p53 KO mice. This conclusion is further supported by an elegant study in which an apoptosisdeficient p53 mutant mouse that retained p53-dependent cell cycle arrest and senescence was still protected from thymic lymphoma development, thus ruling out a role for apoptosis in the tumor-suppressive action of p53 (Liu et al., 2004) . In contrast, evaluation of expression of p16 and p21, regulators of cell cycle arrest and senescence (el-Deiry et al., 1994; Lukas et al., 1995; Alesse et al., 1998; Bringold and Serrano, 2000) revealed differential expression of p21 and p16 in the thymi of the various genotypes (Figure 4c ). These proteins are known to be regulated by sphingolipids such that ceramide induces their expression (Venable and Obeid, 1999; Lee et al., 2000) . Quantitatively, levels of p21, and to a slightly lesser extent p16, closely correlated with the corresponding changes in both ceramide and S1P observed in these tissues (Supplementary Figure 4) , thus, expression of p16 and p21 was decreased in the p53 KO, increased in the SK1 KO, and reverted to near WT levels in the DKO model. These results suggest that the predominant effect of SK1 loss is to restore ceramide and S1P levels and consequently the expression of p16 and p21, which are suppressed in tissues lacking p53.
As both p16 and p21 are important mediators of cell senescence (Jung et al., 2010) , we next evaluated thymus senescence. The results showed that staining for senescence-associated b-galactosidase (b-gal) was profoundly more intense in the DKO tissues than what was observed in the p53 KO tissues (Figure 4d ). These results clearly suggest that induction of senescence is a major response of the DKO cells. Interestingly, the b-gal staining correlated best with the levels of sphingosine (Figure 4a ), which has previously been associated with senescence pathways (Chao et al., 1992; Yoon et al., 2009; Debacq-Chainiaux et al., 2010) . Collectively, these results suggest that by correcting ceramide and S1P levels, and possibly increasing sphingosine, KO of SK1 rectifies the expression of cell cycle inhibitors and induces a strong cellular senescence response to prevent tumor development in p53 KO tissues.
Multiple p53-dependent tumor types are reliant on SK1 Next, we wanted to investigate whether the protective effect of SK1 KO extended to other p53-dependent tumor types in addition to thymic lymphoma. Unlike the aggressive thymic lymphomas observed in p53 KO mice, p53 heterozygote mice tend to develop sarcomas and splenic lymphomas and survive longer than p53 KO mice (Jacks et al., 1994) . Therefore, we crossed p53 heterozygote mice with SK1 KO mice to create p53 þ /À SK1 þ / þ , p53 þ /À SK1 þ /À and p53 þ /À SK1 À/À mice and monitored them for tumor development. The results showed that decreased expression of SK1 protected against tumor development in p53 heterozygote mice (Figure 5a ), with KO of SK1 increasing the percentage of p53 heterozygote mice surviving tumor-free to 42.9% (compared with 7.7% for those expressing both SK1 alleles). KO of SK1 offered substantial protection from the development of lymphoma, osteosarcoma, lung adenocarcinoma and rhabdomyosarcoma in the p53 heterozygote mice (Figure 5a ). Importantly, this decreased tumor burden observed in p53 heterozygote mice lacking SK1 resulted in a 27% increase in their median survival when compared to those with WT SK1 (Figure 5b) . These results indicate a more generalized role for SK1 in p53-induced carcinogenesis that applies to several tissues and types of tumors. Interestingly, analysis of spleens from WT mice and p53 þ /À SK1 WT mice with and without tumors, and spleens from p53 þ /À SK1 KO mice revealed that ceramide levels best matched the expression of cell cycle inhibitors. Whereas normal spleens from p53 heterozygous mice contained less ceramide than WT spleens, this decrease was more profound in tumor tissues from afflicted spleens in the p53 heterozygous mice (Figure 5c ). Importantly, KO of SK1 in p53 heterozygote mice restored ceramide to near WT levels ( Figure 5c ). These differences in ceramide, in turn, closely matched the expression of the cell cycle inhibitors p21 and p16 (Figure 5d ), suggesting that KO of SK1 protects p53 heterozygote mice from tumors through a mechanism similar to that within p53 KO mice. These data suggest that restoring the downregulation of SK1, as seen with WT p53, can, in turn, restore ceramide and cell cycle inhibitor expression to protect p53-deficient mice from the development of various types of tumors, including osteosarcoma and splenic lymphoma as well as thymic lymphoma.
Discussion
This work has identified a novel connection between the p53 pathway and its regulation of sphingolipid metabolism. The results show that p53, through its activation of caspase-2, negatively regulates SK1 in response to genotoxic stress, and that loss of p53 results in significant changes in bioactive sphingolipids through SK1 leading to increased S1P levels and decreased ceramide. Functionally, KO of SK1 significantly increased survival and decreased tumor burden in both p53 KO and p53 heterozygote mice, demonstrating that p53-dependent regulation of SK1 is essential for its Each point represents a mouse that died naturally or was killed because of tumor burden or unthriftiness, whereas the 'n' listed includes mice that are still living, all of which contribute to the survival estimate curve. Differences between the survival curves are statistically significant (by log-rank comparison Po0.02).
(c) Spleens were harvested from mice of the indicated genotypes and phenotypes, homogenized and submitted to lipid analysis. C 16 -ceramide was measured by liquid chromatography-mass spectrometry. Data are averages of lipid levels determined for spleens from three mice and are expressed as pmol lipid per mg protein ± s.e.m. Asterisks indicate statistically significant differences (*Po0.05 by Student's t-test relative to WT or **p53 þ /À SK1 KO relative to p53 þ /À SK1 WT normal or tumor samples.). (d) Protein markers of cell cycle arrest and senescence. Spleens from mice of the indicated genotypes and phenotypes were homogenized, and equal amounts were examined by western blotting.
p53 tumor suppression through SK1 downregulation LA Heffernan-Stroud et al tumor-suppressive effects. This improved survival in p53-deficient mice with KO of SK1 was associated with restoration of sphingolipid homeostasis (decreased S1P and increased ceramide) and induction of cellular senescence in the tissues of these mice.
There is an evolving body of literature supporting a role for SK1 in cancer pathogenesis (Xia et al., 2000; Pitson et al., 2005; Vadas et al., 2008; Bergelin et al., 2009) . SK1 message level is increased in several tumor types (Johnson et al., 2005; Akao et al., 2006; Kawamori et al., 2006; Bayerl et al., 2008) , and knock down of SK1 was shown to be protective from the development of colon cancer in an experimental model of azoxymethaneinduced colon carcinogenesis (Kawamori et al., 2009) . Moreover, it has also been suggested that knockdown of SK2 can slow the growth of breast cancer xenografts through an immune-mediated process (Weigert et al., 2009) . Therefore, several groups are currently working on the production and characterization of selective SK1 and SK2 inhibitors so that their specific roles in anticancer therapies may be better understood (Hengst et al., 2010; Mathews et al., 2010) . Recent studies investigating the application of SK1 inhibitors as anticancer agents have proved promising (Paugh et al., 2008) .
Although not yet commercially available, the same group found that treatment with their SK1 inhibitor could slow the growth of glioblastoma xenografts through the inhibition of Akt (Kapitonov et al., 2009) . Interestingly, some recently developed SK1 inhibitors work through proteasomal degradation of SK1 (Loveridge et al., 2010) , further supporting that proteolysis may be an important mechanism of SK1 regulation as suggested by our study. As selective inhibitors are developed and made commercially available, their in vivo optimization will allow for investigation as to whether the tumor-protective effect of SK1 KO found in this study can in fact be mimicked pharmacologically.
Finally, in this report, we uncover tumor cell senescence as a novel mechanism by which loss of SK1 is protective from tumor development. Moreover, the associated changes in sphingolipid profile and protein expression could mechanistically explain the increased proliferation in p53 KO tumors and the protective senescence response in DKO mice. The results clearly show significant derangement in ceramide, sphingosine and S1P levels in p53 knock out cells and tissues and in p53 KO-induced tumors. These changes occur in directions known to promote carcinogenesis (decreased ceramide and increased S1P) (Ogretmen and Hannun, 2004; Taha et al., 2006; Hannun and Obeid, 2008) . Together with previous studies demonstrating the p53-dependent effects on ceramide in human leukemia and neuroblastoma cell lines as well as in mouse fibroblasts (Dbaibo et al., 1998; Kim et al., 2002) , our data suggest that the major effect of p53 on sphingolipid metabolism is to induce proteolysis of SK1 (Taha et al., 2004) , which subsequently leads to ceramide accumulation and loss of S1P. As SK1 KO could potentially be mimicked by treatment with a small molecule inhibitor, this method of inducing tumor cell senescence may offer a promising therapeutic avenue for patients with altered p53 status, which has proved to be an elusive aspect of cancer therapy for many years.
Materials and methods
Reagents
Experiments using these reagents were deleted during the review process. For western blots (specific procedures detailed in Supplementary Materials and methods), we used complete-mini protease inhibitor tablets (Roche, Indianapolis, IN, USA), RIPA buffer (Boston Bioproducts, Ashland, MA, USA), bicinchoninic acid protein assay (Pierce, Rockford, IL, USA) and precast 10% Tris-HCl gels (Bio-Rad, Hercules, CA, USA). Senescenceassociated b-gal staining kits were purchased from Cell Signaling (Danvers, MA, USA). SK1 primary antibodies against human SK1 (MUSC, Charleston, SC, USA) and against mouse SK1 (Fisher/Open Biosystems, Huntsville, AL, USA) were custom made for our laboratory. Other primary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated secondary antibodies were obtained from Jackson Labs (Bar Harbor, ME, USA), except for rabbit secondary which was purchased from Santa Cruz Biotechnology.
Cell culture
Following harvest, MEFs were maintained in Dulbecco's modified Eagles medium containing high glucose (Gibco, Grand Island, NY, USA), supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Gibco or Hyclone, Logan, UT, USA) and 1% (v/v) antimycotic-antibiotic solution (Gibco). Cells were kept in a humidified incubator at 37 1C with 5% CO 2 . Where indicated, ultraviolet irradiation of cells was performed using a Bio-Rad GS Gene Linker cabinet that emits UVC light (l ¼ 253.7 nm).
Animals
Under our protocol, ARC# 2690, which was approved by the MUSC IACUC, we created a breeding colony of C57BL/6 mice with varying p53 and SK1 status. The SK1 KO mice were originally obtained from Dr R Proia (Allende et al., 2004) crossbred with WT C57BL/6 mice in the DLAR at MUSC and maintained as an SK1 KO colony. Two male p53 heterozygote mice were obtained from the laboratory of Dr C Schweinfest and bred as previously described (Jacks et al., 1994) and additional p53 heterozygote breeders were purchased from Jackson Labs (stock number 002101). Genotyping of mice was performed using a Qiagen (Valencia, CA, USA) DNAeasy Blood and Tissue kit and specific primers from IDT (Coralville, IA, USA). Mating pairs of p53 þ /À SK1 þ /À or WT or SK1 KO mice were set up and MEFs were harvested and genotyped between embryonic day 12.5-14.5 of gestation. Further breeding and genotyping information and MEF collection details are provided in the Supplementary Information.
Assessing survival
Mice were monitored daily for tumor development and general health by an unbiased caretaker. Mice that appeared to be suffering or in pain, unable to eat or immobile were killed and necropsied. Survival was measured by the number of days between each mouse's date of birth and date of death, or date of euthanization due to humane reasons. Runts and mice with genetic issues common to the C57BL/6 background, namely blindness and malocclusion, were killed and not included in the survival study. Assessing tumor burden At 4 months of age, p53 KO mice harboring each possible SK1 genotype: WT, HZ or KO, were killed and necropsied with the assistance of a veterinary pathologist (KLH). Each organ was inspected and weighed, and then representative sections were fixed for histological evaluation. Thymic mass was the primary indicator of tumor burden in the p53 KO mice, whereas, p53 HZ mice suffered a more diverse range of tumors with more varied latency. Thus, p53 HZ mice were killed and necropsied at different ages because of individual unthriftiness, or they were necropsied after they were found dead to determine tumor burden. Each organ was inspected and any abnormal tissues or masses were fixed for histological evaluation by KLH.
Animal imaging
Micro-magnetic resonance imaging of mice was performed by Dr P Chou under the guidance of Dr B Memet in the MUSC Animal Imaging Core Facility with a 7T MR Bruker Biospec USR (Bruker Inc., Billerica, MA, USA) actively shielded scanner with a 30-cm horizontal bore and Paravision software (Bruker Inc., Billerica, MA, USA).
Tissue homogenization
Following tissue collection as described in Supplementary Materials and methods, tissues were minced with dissecting scissors in 350 ml of SK1 lysis buffer or RLT buffer (Qiagen) in a 2-ml microcentrifuge tube before being homogenized on ice with a handheld Tissue Tearor (Biospec, Bartlesville, OK, USA) set at level 25 for 1 min. Samples were then transferred to a clean microcentrifuge tube and sonicated for 10 s to ensure homogeneity before being aliquoted for protein or other analysis.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were hydrated through histoclear and an ethanol gradient, slides were boiled in citrate buffer for antigen retrieval, and they were immersed in 10% H 2 O 2 in methanol to quench endogenous peroxide activity. Sections were then blocked with normal serum and incubated overnight at 4 1C with rabbit anti-SK1 primary antibody followed by a 30-min incubation with biotinylated anti-rabbit immunoglobulin G, and then avidin biotin complex-horseradish peroxidase (Vector Laboratories, Burlingame, CA, USA). The slides were then developed with DAB/ H2O2 (Thermo Scientific, Hudson, NH, USA), counterstained with hematoxylin, and dehydrated with an ethanol gradient and Histoclear.
Senescence-associated b-gal Staining Frozen 10-mm sections of thymi were fixed in 0.2% glutaraldehyde/phosphate-buffered saline for 10 min at 4 1C, washed with phosphate-buffered saline (pH 6.0), stained with the senescence-associated b-gal staining kit (Cell Signaling) overnight at 37 1C, washed with H 2 O, counterstained with eosin and dehydrated in an ethanol gradient with histoclear as previously described (Sun et al., 2007) .
SK1 activity assay
After tissue homogenization in SK1 lysis buffer, either an aliquot of protein (30 mg) from each homogenized tissue sample, or 30 ml of sample was normalized to its protein concentration and assayed for sphingosine kinase activity in the presence of 32 P-ATP and sphingosine for 30 min at 37 1C. At the end of the reaction, lipids were extracted and subjected to thin layer chromatography (TLC).
32 P-S1P was measured using autoradiography. Quantification of S1P-specific radioactivity was performed by scraping the S1P-specific bands into scintillation vials that had their contents quantified via scintillation counting.
Sphingolipidomic analysis
Cell samples were prepared as detailed in Supplementary Materials and methods. Each sample was vortexexed and then 250 ml was aliquoted into a labeled 15-ml conical flask. This and the remaining sample in a 1.5-ml microcentrifuge tube were then snap frozen in a dry ice/methanol bath and frozen at À80 1C before sphingolipidomic analysis or bicinchoninic acid (BCA) protein assay, respectively. Tissue samples were homogenized as described above and, after protein analysis, an aliquot of homogenized sample (1 mg protein) was transferred to a 15-ml conical flask and frozen at À80 1C until sphingolipidomic analysis. Alternatively, 100 ml of homogenized sample was submitted and lipids were subsequently corrected to the sample protein concentration. Sphingolipid masses were determined by electrospray ionization tandem mass spectrometry (ESI/MS/MS). Analysis of ceramides, sphingosine, and S1P was performed on a Thermo Finnigan TSQ 7000 triple quadrupole mass spectrometer operating in a multiple reaction-monitoring positive ionization mode, as described .
Statistical analysis
Data are represented as mean±s.e.m., unless otherwise indicated. Unpaired Student's t-test, one-way analysis of variance with Dunnett's post test or log-rank test statistical analyses were performed using Prism/GraphPad software (La Jolla, CA, USA).
